Want to see NRIX full AI Analyst Report?
Top Page
Nurix Therapeutics
(NASDAQ:NRIX)
Select Model
Select Model
Rating:57Neutral
Price Target:
$26.00
▼(-3.27% Downside)
Action:Reiterated
Date:10/13/26
The score is primarily supported by improved TTM financial performance (positive earnings and strong cash flow with modest leverage), but is held back by weak technical signals (below key moving averages with negative MACD) and an unclear valuation picture due to a negative P/E and no dividend yield provided.
Positive Factors
Revenue and Profit Inflection
The sharp TTM increase in revenue, together with a return to positive operating profit and net income, indicates meaningful recent business improvement. If this reflects advancing partnered programs and repeatable collaboration activity, it could materially strengthen Nurix’s earnings base over the next several quarters.
Negative Factors
Long History of Losses
Several years of sizable operating and net losses show that the recent earnings improvement has not yet established a durable profitability record. This history highlights the company’s exposure to biotech earnings volatility and means future performance may still depend on uneven development or partnership outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and Profit Inflection
The sharp TTM increase in revenue, together with a return to positive operating profit and net income, indicates meaningful recent business improvement. If this reflects advancing partnered programs and repeatable collaboration activity, it could materially strengthen Nurix’s earnings base over the next several quarters.
Read all positive factors
Nurix Therapeutics Key Performance Indicators (KPIs)
Any
Revenue by Segment
Breaks down revenue by different business segments, highlighting which areas are driving growth and which may need strategic adjustments. This insight helps assess the company's diversification and focus.
Breaks down revenue by different business segments, highlighting which areas are driving growth and which may need strategic adjustments. This insight helps assess the company's diversification and focus.
Data provided by:
The Fly
The FlyNurix Therapeutics (NRIX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.77B
Dividend YieldN/A
Average Volume (3M)2.11M
Price to Earnings (P/E)10.1
Beta (1Y)1.17
Revenue Growth738.76%
EPS GrowthN/A
CountryUS
Employees317
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)2.51
Shares Outstanding109,249,820
10 Day Avg. Volume3,316,077
30 Day Avg. Volume2,112,400
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)2.72
Price to Sales (P/S)17.45
P/FCF Ratio-5.56
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue2.87
Enterprise Value/Gross Profit3.31
Enterprise Value/Ebitda6.24
Forecast
1Y Price Target
$34.50Price Target Upside28.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)2.35
Revenue Forecast (FY)$681.80M
Nurix Therapeutics Business Overview & Revenue Model
Company Description
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. T...
How the Company Makes Money
Nurix primarily makes money through (1) collaboration and license revenue from partnerships with larger biopharmaceutical companies and (2) to a lesser extent, other operating revenues typical of a clinical-stage biotech (e.g., research-related re...
Nurix Therapeutics Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
74
Positive
Cash Flow
68
Positive
| Breakdown | TTM | Nov 2025 | Nov 2024 | Nov 2023 | Nov 2022 | Nov 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 701.94M | 83.98M | 54.55M | 76.99M | 38.63M | 29.75M |
| Gross Profit | 607.18M | 65.12M | -167.08M | -112.16M | -145.87M | -86.68M |
| EBITDA | 322.61M | -244.84M | -176.87M | -130.29M | -169.55M | -110.98M |
| Net Income | 294.88M | -264.46M | -193.57M | -143.95M | -180.36M | -117.19M |
Balance Sheet | ||||||
| Total Assets | 1.20B | 688.13M | 669.34M | 355.60M | 416.76M | 476.77M |
| Cash, Cash Equivalents and Short-Term Investments | 1.05B | 592.94M | 609.58M | 287.91M | 309.14M | 295.72M |
| Total Debt | 65.33M | 55.73M | 28.30M | 30.61M | 11.96M | 13.04M |
| Total Liabilities | 226.99M | 149.39M | 142.35M | 155.10M | 113.06M | 134.47M |
| Stockholders Equity | 968.31M | 538.75M | 526.99M | 200.49M | 303.70M | 342.30M |
Cash Flow | ||||||
| Free Cash Flow | 369.81M | -263.47M | -181.86M | -89.77M | -172.05M | -90.03M |
| Operating Cash Flow | 379.31M | -249.47M | -172.58M | -81.36M | -159.81M | -84.36M |
| Investing Cash Flow | 1.10M | 147.85M | -257.71M | 68.30M | 27.20M | -108.25M |
| Financing Cash Flow | 261.21M | 238.64M | 485.67M | 3.22M | 117.19M | 153.88M |
Nurix Therapeutics Technical Analysis
Positive
26.88
Price Trends
25.03
Positive
23.45
Positive
19.98
Positive
Market Momentum
0.27
Negative
57.74
Neutral
85.56
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRIX, the sentiment is Positive. The current price of 26.88 is above the 20-day moving average (MA) of 23.77, above the 50-day MA of 25.03, and above the 200-day MA of 19.98, indicating a bullish trend. The MACD of 0.27 indicates Negative momentum. The RSI at 57.74 is Neutral, neither overbought nor oversold. The STOCH value of 85.56 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NRIX.
Nurix Therapeutics Risk Analysis
Nurix Therapeutics disclosed 81 risk factors in its most recent earnings report. Nurix Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nurix Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $2.77B | 10.10 | 49.34% | ― | 738.76% | ― | |
56 Neutral | $3.94B | -27.46 | -25.74% | ― | 121.47% | 36.95% | |
55 Neutral | $3.98B | -11.58 | -42.27% | ― | 23.86% | 19.60% | |
54 Neutral | $1.37B | -9.76 | -35.35% | ― | ― | 28.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $924.80M | -4.97 | -43.31% | ― | -83.86% | -646.52% |
* Healthcare Sector Average
NRIX
Nurix Therapeutics
25.34
14.25
128.49%
ORIC
Oric Pharmaceuticals
13.17
0.07
0.53%
RLAY
Relay Therapeutics
18.18
11.32
165.01%
TNGX
Tango Therapeutics
23.34
15.84
211.20%
GLUE
Monte Rosa Therapeutics
10.84
-0.30
-2.69%
ODTX
Odyssey Therapeutics, Inc.
19.60
3.18
19.37%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.